ODAC review rescheduled for CTI's pixantrone

Seattle-based Cell Therapeutics (CTI) announced today that their rescheduled day of reckoning will now be on March 22, 2010. This is the day when the FDA's Oncologic Drugs Advisory Committee (ODAC) will meet to properly review CTI's new drug application for pixantrone as a treatment for diffuse large B-cell lymphoma (DLBCL).

This review should have taken place back in February but was postponed by bad weather.

The Oncologic Drugs Advisory Committee is an independent panel of experts which evaluates the performance of cancer drugs and, based on that evaluation, makes recommendations to the FDA regarding approval or rejection.

The FDA has final approval and is not beholden to the recommendation of the ODAC. The agency is scheduled to announce its final decision regarding pixantrone on April 23, 2010.

By Ross Bonander

Information on pixantrone from Cell Therapeutics

More Articles

More Articles

This entry looks at what is sometimes referred to as mesenteric lymphoma, also referred to as non-Hodgkin's...

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

B cell lymphoma is not one disease but a few dozen heterogeneous diseases, or individual cancers, that affect the b...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Also known as Hodgkin's disease, Hodgkin's lymphoma (HL) is a cancer of the white blood cells, or...

Canine lymphoma, just like lymphoma in humans, can be separated into stages,...

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

It's not uncommon for patients with some lymphomas to experience itching (clinically known as pruritus). Lymphoma itching symptoms can range from...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...